innovation compounding semaglutide Despite FDA ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market Innovative Primary Care Helps Patients

More than one in four believe weight loss will increase their perceived leadership ability, while 23% say it could expand their job or promotion opportunities

This is a company pulling away from its only meaningful rival while raising guidance into a year everyone thought would bring pricing pressure

However, in South Africa, only Saxenda is approved for the treatment of obesity

* Correspondence: Emel Cengiz Kaynakc, [email protected] ORCID: Emel Cengiz Kaynakc orcid.org/0000-0002-2152-0262 Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

For those Noom considers qualified, the goal is improved metabolic health over timemeasured through biomarkers such as HbA1c and cholesterol rather than short-term weight loss

2025;9:bvaf149.074